• OPEN AN ACCOUNT
Indian Indices
Sensex
71,909.70 -570.59
( -0.79%)
Global Indices
Nasdaq
50,952.25 25.20
(0.05%)
Dow Jones
7,687.74 15.20
(0.20%)
Hang Seng
68,256.51 -700.21
(-1.02%)
Nikkei 225
10,455.36 27.09
(0.26%)
Forex
USD-INR
95.92 -0.05
(-0.05%)
EUR-INR
108.79 -0.10
(-0.09%)
GBP-INR
127.19 0.21
(0.17%)
JPY-INR
0.61 0.00
(0.14%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

Lupin receives USFDA approval for Modafinil Tablets USP
Sep 04,2026
Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, 100 mg and 200 mg.

The U.S. FDA has approved Lupin's Modafinil Tablets USP, 100 mg and 200 mg as bioequivalent to the reference listed drug (RLD), Provigil® Tablets of Nuvo Pharmaceuticals (Ireland) DAC, and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA) or shift work disorder (SWD).

Modafinil Tablets (RLD Provigil®) had estimated annual sales of USD 70.7 million in the U.S. (IQVIA MAT Jul 2026).